John Libbey Eurotext

European Journal of Dermatology

MENU

Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases Volume 28, numéro 1, January-February 2018

Illustrations

  • Figure 1
  • Figure 2
  • Figure 3
Auteurs
1 Division of Medical Oncology,
2 Institute of Pathology,
3 Institute of Radiology and Nuclear Medicine,
4 Division of Dermatology, Lucerne Cantonal Hospital and Cancer Center, 6000 Lucerne, Switzerland
* Reprints
  • Mots-clés : PD1 checkpoint inhibitor, nivolumab, off-label, skin cancer
  • DOI : 10.1684/ejd.2017.3209
  • Page(s) : 78-81
  • Année de parution : 2018

Background

Programmed cell death ligand 1 (PD-L1) is frequently expressed in cutaneous squamous cell cancer (CSCC) and preliminary data from an ongoing clinical trial suggest that programmed death receptor 1 (PD-1) checkpoint inhibitors may be useful to treat patients with metastatic non-melanoma skin cancer.